Eli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry

With a five-year EPS forecast of 28.38%, Eli Lilly and Company (NYSE:LLY) is among the 12 Best Future Stocks to Buy Right Now.

On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in higher-BMI participants, while also delivering broad improvements across key cardiometabolic risk markers. Wolfe Research described the results as setting a new benchmark in next-generation obesity therapeutics, noting that the data further strengthens Lilly’s leadership and differentiation within the rapidly expanding GLP-1 market, while reiterating an Outperform rating and $1,350 price target on the shares.

A day earlier, Engage Biologics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). Engage is developing the Tethosome platform, a non-viral DNA delivery technology designed to address longstanding challenges in DNA delivery, including potency, tolerability, and repeat dosing. Lilly agreed to acquire the company for up to $202 million in cash, consisting of an upfront payment and additional milestone-based payments tied to development progress, expanding its pipeline and reinforcing its commitment to next-generation drug delivery innovation.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader focused on the research, development, and manufacturing of innovative medicines. The company concentrates on major therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience, positioning itself at the forefront of some of the fastest-growing segments in healthcare. It is headquartered in Indianapolis, Indiana, and was founded in 1876.

READ NEXT: 7 Best Heavy Equipment Stocks to Buy as Backlogs Hit Records and 9 Best Natural Gas Stocks to Buy for Transitional Power.

Disclosure: None.  Follow Insider Monkey on Google News.